NextFin News - A research team led by Utah State University and University of Utah Health has unveiled a transformative CRISPR technology that functions as a "molecular shredder" to selectively eliminate cancer and virus-infected cells. Unlike the widely known CRISPR-Cas9, which acts as precision scissors to edit specific DNA sequences, the newly detailed Cas12a2 protein is triggered by specific RNA sequences to indiscriminately destroy all DNA within a targeted cell, effectively forcing it to self-destruct. The findings, published May 6 in the journal Nature, represent a significant shift from gene correction toward sequence-specific cellular execution.
The study demonstrates that Cas12a2 can be programmed to recognize a single-point mutation in the KRAS gene, a common driver of lung, colorectal, and pancreatic cancers. In laboratory settings, the treatment reduced the growth of human lung cancer cells by approximately 50%, a performance comparable to the chemotherapy drug cisplatin. Crucially, the researchers reported that the enzyme left healthy cells with normal KRAS genes entirely untouched. Ryan Jackson, an associate professor at Utah State University and co-corresponding author, noted that the system’s high specificity allows it to spare healthy tissue even when the genetic difference is as minute as a single nucleotide.
Beyond oncology, the technology showed high efficacy against infectious diseases. Collaborating with Akribion Therapeutics, the team targeted RNA from the human papillomavirus (HPV). The treatment reduced the growth of infected cells by more than 90% in vitro. In animal models, a single injection of HPV-targeted Cas12a2 into tumors in mice resulted in a 50% reduction in tumor volume. Yang Liu, an assistant professor at University of Utah Health, emphasized that the enzyme’s primary function is total destruction rather than repair, describing it as a tool designed to "destroy anything it sees" once the specific RNA trigger is detected.
While the results have generated optimism within the biotechnology sector, the transition from "cells in a dish" to human clinical applications remains a formidable hurdle. Jared Thompson, a graduate researcher at University of Utah Health and co-first author, cautioned that the systemic effects of Cas12a2 on an entire organism are not yet fully understood. There are significant concerns regarding how different organ systems might uptake the protein and whether its mere presence, even when not activated by a target RNA, could trigger unintended immune responses or toxicity. Furthermore, delivering the CRISPR machinery effectively to deep-seated tumors or specific infected tissues remains a primary engineering challenge for the industry.
The commercial potential of Cas12a2 extends into agriculture and diagnostics, where the ability to selectively eliminate cells harboring specific pathogens could revolutionize crop protection and rapid testing. However, the current data is largely derived from a single primary research group and its immediate collaborators, meaning these findings have yet to be widely replicated by independent commercial labs or large-scale pharmaceutical trials. From a market perspective, this technology is in the early "proof-of-concept" stage; it represents a high-risk, high-reward frontier in synthetic biology rather than an imminent replacement for existing gene-editing or oncology standards.
Explore more exclusive insights at nextfin.ai.
